Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants
News
A new Phase 3 trial will evaluate the potential of Tecentriq (atezolizumab) as an add-on therapy to Avastin (bevacizumab) plus chemotherapy in advanced ovarian cancer patients. The trial, called ATALANTE (NCT02891824), ... Read more